{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6"},{"groupId":"OG001","value":"98.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"562"},{"groupId":"OG001","value":"281"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.","groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle. Qualified participants who received first course of pembrolizumab but continued to experience disease progression were eligible to initiate a second course of pembrolizumab IV Q3W for up to 17 administrations (up to \\~1 year).","id":"OG000","title":"Part 2: Pembrolizumab + Chemotherapy"},{"description":"Participants received placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel 100 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m\\^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study intervention. Participants were included in the group corresponding to the study intervention actually received.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Part 2: Percentage of Participants Who Experienced an AE- All Participants","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}